Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell, Luc G.T. Morris, Claud M. Grigg et al. · Science · 2017
HLA genotype affects response Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516
Cited by 1,132 works. doi:10.1126/science.aao4572
Authors
- Diego Chowell
- Luc G.T. Morris
- Claud M. Grigg
- Jeffrey K. Weber
- Robert M. Samstein
- Vladimir Makarov
- Fengshen Kuo
- Sviatoslav M. Kendall
- David Requena
- Nadeem Riaz
- Benjamin D. Greenbaum
- Edward B. Garon
- David Michael Hyman
- Ahmet Zehir
- David B. Solit
- Michael F. Berger
- Ruhong Zhou
- Naiyer A. Rizvi
- Timothy An-thy Chan
References
- Fast and accurate short read alignment with Burrows–Wheeler transform
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- VMD: Visual molecular dynamics
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- Scalable molecular dynamics with NAMD
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency